INSANE: Novo nordisk | Vintage Vibes

Zepbound Sales Climb 49% to $5.35 Billion as Lilly Sells More Weight-Loss Medicine at Lower Prices

Eli Lilly reported $5.35 billion in third-quarter Zepbound sales, up 49%, as volume rose 53% and realized prices fell 15%, highlighting strong GLP-1 demand and ongoing affordability challenges.

Medical Daily · 12h ago

Employer GLP-1 Coverage Falls to 53% as Workers Losing Wegovy or Zepbound in 2027 Weigh Prices and Appeals

Employer coverage of GLP-1 drugs for weight loss has declined, prompting workers to review plan changes, compare self-pay options, and discuss appeals or treatment transitions with clinicians.

Medical Daily · Oct 30

Dear Eli Lilly Stock Fans, Mark October 29 on Your Calendar

Eli Lilly’s weight-loss boom faces fierce competition, but its next earnings report could reveal why the best may still be ahead.

Barchart · Oct 26

Ozempic and Zepbound Makers Report Slower Aging Clocks, but Unreviewed Data Do Not Prove Patients Age Slower

Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know.

Medical Daily · Oct 8

Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’

Investors say Novo Nordisk's results are among the best ever. Here's what their CEO says about why the stock price hasn't caught up yet.

Barchart · Oct 8

Manufacturing Site Problems, Not Trial Results, Push Back FDA Decision on Novo's Once-Monthly Hemophilia A Drug Denecimig

FDA's review of Novo's hemophilia A drug denecimig is delayed by manufacturing site issues, not trial data. Launch is now targeted for 2027.

Medical Daily · Oct 5

NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.

Eli Lilly continues to outpace Novo Nordisk in the weight-loss market, supported by stronger patient growth and market share gains.

Barchart · Oct 5

Postpartum GLP-1 Prescriptions Rose Nearly 24-Fold Among Privately Insured New Mothers, with Breastfeeding Safety Data Still Limited

A JAMA study of 1 million births found postpartum GLP-1 prescriptions rose nearly 24-fold. What new mothers should know about breastfeeding and cost.

Medical Daily · Oct 4

Liver Fat Fell to Normal in 23 of 26 Adults with Obesity in Small Wegovy Post Hoc Analysis

In a small Novo Nordisk analysis, 23 of 26 adults with obesity and excess liver fat reached normal levels on semaglutide. Here is what the numbers do and do not show.

Medical Daily · Oct 3

Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears

Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.

Medical Daily · Oct 2